Full TitleAHEP1531, Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) (CIRB)
The purpose of this study is to evaluate several new approaches to treating liver cancers (hepatoblastoma and hepatocellular carcinoma) in children, adolescents, and young adults. Patients will be placed in a treatment group according to their type of liver cancer and how aggressive it may be (i.e., low, intermediate, or high risk, operable, inoperable, or metastatic). This study includes groups for children with these types of cancers:
- Very low-risk hepatoblastoma
- Low-risk hepatoblastoma
- Intermediate-risk hepatoblastoma
- High-risk hepatoblastoma
- Initially operable hepatocellular carcinoma
- Initially inoperable or metastatic hepatocellular carcinoma
The treatments include a combination of intravenous chemotherapy (given by vein) and oral drugs (taken by mouth), depending on which group a patient is placed in. In some cases, patients will not receive chemotherapy after surgery, but will be observed. Other patients will receive chemotherapy before surgery to see if it shrinks the tumor enough to make it operable.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- This study is for patients age 30 and younger.
- Patients must have hepatoblastoma or hepatocellular carcinoma.
- Prior liver cancer surgery is permitted, but patients may not have received any other treatment for liver cancer.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.